These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37540268)

  • 1. Objective Definition and Optimized Strategy for "Biologically Borderline Resectable" Colorectal Liver Metastases.
    Takamoto T; Nara S; Ban D; Mizui T; Murase Y; Esaki M; Shimada K; Hashimoto T; Makuuchi M
    World J Surg; 2023 Nov; 47(11):2834-2845. PubMed ID: 37540268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis.
    Ono K; Abe T; Oshita A; Sumi Y; Yano T; Okuda H; Kurayoshi M; Kobayashi T; Ohdan H; Noriyuki T; Nakahara M
    World J Surg Oncol; 2021 Apr; 19(1):97. PubMed ID: 33820549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study.
    Hirokawa F; Ueno M; Nakai T; Kaibori M; Nomi T; Iida H; Tanaka S; Komeda K; Hayami S; Kosaka H; Hokuto D; Kubo S; Uchiyama K
    J Gastrointest Surg; 2022 Apr; 26(4):772-781. PubMed ID: 34664190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Borderline resectable for colorectal liver metastases: Present status and future perspective.
    Kitano Y; Hayashi H; Matsumoto T; Kinoshita S; Sato H; Shiraishi Y; Nakao Y; Kaida T; Imai K; Yamashita YI; Baba H
    World J Gastrointest Surg; 2021 Aug; 13(8):756-763. PubMed ID: 34512899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases.
    Ninomiya M; Emi Y; Motomura T; Tomino T; Iguchi T; Kayashima H; Harada N; Uchiyama H; Nishizaki T; Higashi H; Kuwano H
    Int J Clin Oncol; 2021 Dec; 26(12):2255-2264. PubMed ID: 34519930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis.
    Chen FL; Wang YY; Liu W; Xing BC
    Front Oncol; 2022; 12():973418. PubMed ID: 36132151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
    Bao Q; Wang K; Wang HW; Jin KM; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study.
    Jiang YJ; Zhou SC; Chen JH; Liang JW
    Front Oncol; 2022; 12():951540. PubMed ID: 36330479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?
    Hirokawa F; Asakuma M; Komeda K; Shimizu T; Inoue Y; Kagota S; Tomioka A; Uchiyama K
    Surg Today; 2019 Jan; 49(1):82-89. PubMed ID: 30255329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
    Kobayashi S; Takahashi S; Nomura S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N; Taniguchi H; Yoshino T
    Cancer Med; 2021 Oct; 10(20):6998-7011. PubMed ID: 34535965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Unresectable Recurrence After Up-Front Surgery for Colorectal Liver Metastasis.
    Hokuto D; Nomi T; Yasuda S; Yoshikawa T; Ishioka K; Yamada T; Akahori T; Nakagawa K; Nagai M; Nakamura K; Obara S; Kanehiro H; Sho M
    World J Surg; 2018 Mar; 42(3):884-891. PubMed ID: 28879511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
    Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
    J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
    Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
    Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined ablation and resection (CARe) for resectable colorectal cancer liver Metastases-A propensity score matching study.
    Liu M; Wang Y; Wang K; Bao Q; Wang H; Jin K; Liu W; Yan X; Xing B
    Eur J Surg Oncol; 2023 Sep; 49(9):106931. PubMed ID: 37183048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study.
    Kitano Y; Ono Y; Kobayashi K; Oba A; Sato T; Ito H; Inoue Y; Shinozaki E; Yamaguchi K; Saiura A; Baba H; Takahashi Y
    HPB (Oxford); 2024 Feb; 26(2):282-290. PubMed ID: 37985325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis.
    Zhang Y; Ge L; Weng J; Tuo WY; Liu B; Ma SX; Yang KH; Cai H
    World J Clin Cases; 2021 Aug; 9(22):6357-6379. PubMed ID: 34435001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation Prolongs Survival for Ablatable Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study.
    Chen Y; Xu Y; Xu L; Han F; Huang Y; Jiang H; Wu J; Zhang Y
    Front Oncol; 2021; 11():758552. PubMed ID: 34745996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D; Hollande F; Michael M; Hayes I; Heriot A; Knowles B; Thomson B
    ANZ J Surg; 2021 Jun; 91(6):1196-1202. PubMed ID: 33543551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation May Be a New Treatment Modality for Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study.
    Chen Y; Huang Y; Xu L; Wu J; Han F; Jiang H; Zheng P; Xu D; Zhang Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.